The First Comprehensive Cohort of the Duchenne Muscular Dystrophy in Iranian Population: Mutation Spectrum of 314 Patients and Identifying Two Novel Nonsense Mutations

被引:0
|
作者
Gholamreza Zamani
Ali Hosseini Bereshneh
Reza Azizi Malamiri
Sayna Bagheri
Kamyar Moradi
Mahmoud Reza Ashrafi
Ali Reza Tavasoli
Mahmoud Mohammadi
Reza Shervin Badv
Masood Ghahvechi Akbari
Morteza Heidari
机构
[1] Tehran University of Medical Sciences,Pediatrics Center of Excellence, Department of Pediatric Neurology, Children’s Medical Center
[2] Shiraz University of Medical Sciences,Prenatal Diagnosis and Genetic Research Center, Dastgheib Hospital
[3] Shiraz University of Medical Sciences,Department of Medical Genetics, School of Medicine
[4] Ahvaz Jundishapur University of Medical Sciences,Department of Pediatric Neurology, Golestan Medical, Educational, and Research Center
[5] Tehran University of Medical Sciences,Faculty of Medicine, Students’ Scientific Research Center
[6] Tehran University of Medical Sciences,Pediatrics Center of Excellence, Department of Pediatric Neurology, Children’s Medical Center, Growth and Development Research Center
[7] Tehran University of Medical Sciences,Department of Physical Medicine and Rehabilitation, Children’s Medical Center
[8] Tehran University of Medical Sciences,Department of Pediatric Neurology, Vali
来源
关键词
Duchenne muscular dystrophy; MLPA; Dystrophin mutation; NGS; Iranian patients;
D O I
暂无
中图分类号
学科分类号
摘要
Mutations in the dystrophin gene could cause Duchenne muscular dystrophy (DMD), which is the most common muscular disorder in pediatrics. Considering the growing evidence on appropriateness of gene therapies for DMD, precise genetic diagnosis seems essential. Hence, we conducted a study to determine mutational patterns in Iranian children with DMD. To detect all probable large mutations in the dystrophin gene, 314 DMD patients were evaluated using the multiplex ligation-dependent probe amplification (MLPA). Subjects who were MLPA-negative underwent the next generation sequencing (NGS) to identify potential point mutations. MLPA detected deletions (79.93%) and duplications (5.41%) along the dystrophin gene of 268 patients. Distribution of large mutations was heterogeneous and followed hotspot pattern throughout the gene. From 46 patients who were MLPA-negative, 43 exhibited point mutations including nonsense in 7.64%, frameshifts in 4.77%, splicing in 0.96%, and missense variations in 0.32% of participants. Most of the point mutations were located between exons 19 and 40. In three patients (1%), no mutation was found using either MLPA or NGS. Two subjects had novel nonsense mutations (L1675X and E1199X) in their dystrophin gene, which were considered as the possible reason for elimination of major domains of the gene. The results of this study provided invaluable information regarding the distribution of various large and small mutations in Iranian individuals with DMD. Besides, the novel nonsense mutations L1675X and E1199X were identified within the highly conserved residues, leading to elimination of significant domains of the dystrophin gene.
引用
收藏
页码:1565 / 1573
页数:8
相关论文
共 50 条
  • [1] The First Comprehensive Cohort of the Duchenne Muscular Dystrophy in Iranian Population: Mutation Spectrum of 314 Patients and Identifying Two Novel Nonsense Mutations
    Zamani, Gholamreza
    Bereshneh, Ali Hosseini
    Malamiri, Reza Azizi
    Bagheri, Sayna
    Moradi, Kamyar
    Ashrafi, Mahmoud Reza
    Tavasoli, Ali Reza
    Mohammadi, Mahmoud
    Badv, Reza Shervin
    Akbari, Masood Ghahvechi
    Heidari, Morteza
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2020, 70 (10) : 1565 - 1573
  • [2] High frequency of nonsense mutations in Russian patients with Duchenne muscular dystrophy
    Zinina, Elena
    Bulakh, Maria
    Chukhrova, Alena
    Shchagina, Olga
    Polyakov, Aleksander
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2023, 31 : 215 - 215
  • [3] Meta-analyses of ataluren in patients with nonsense mutation Duchenne muscular dystrophy
    Muntoni, F.
    Mercuri, E.
    Luo, X.
    Elfring, G.
    Werner, C.
    Trifillis, R.
    Peltz, S. W.
    McDonald, C. M.
    NEUROMUSCULAR DISORDERS, 2018, 28 : S12 - S12
  • [4] Meta-Analyses of Ataluren in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
    Campbell, C.
    Muntoni, F.
    Mercuri, E.
    Luo, X.
    Elfring, G.
    Kroger, H.
    Riebling, P.
    Ong, T.
    Spiegel, R.
    Peltz, S.
    McDonald, C.
    ANNALS OF NEUROLOGY, 2016, 80 : S365 - S365
  • [5] META-ANALYSES OF ATALUREN IN PATIENTS WITH NONSENSE MUTATION DUCHENNE MUSCULAR DYSTROPHY (NMDMD)
    Butterfield, Russell J.
    Luo, Xiaohui
    Elfring, Gary
    Kroger, Hans
    Riebling, Peter
    McIntosh, Joseph
    Ong, Tuyen
    Spiegel, Robert
    Peltz, Stuart W.
    McDonald, Craig
    MUSCLE & NERVE, 2016, 54 : 12 - 13
  • [6] Demographics of patients with nonsense mutation Duchenne muscular dystrophy receiving ataluren in the STRIDE Registry
    Muntoni, F.
    Mercuri, E.
    Buccella, F.
    Desguerre, I.
    Kirschner, J.
    Nascimento Osorio, A.
    Tulinius, M.
    Jiang, J.
    Kristensen, A.
    Johnson, S.
    Able, R.
    Trifillis, P.
    Santos, C.
    NEUROMUSCULAR DISORDERS, 2020, 30 : S62 - S62
  • [7] Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients?
    Yokota, Toshifumi
    Duddy, William
    Echigoya, Yusuke
    Kolski, Hanna
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (09) : 1141 - 1152
  • [8] Safety and Tolerability of Ataluren in a Phase 3 Study of Patients with Nonsense Mutation Duchenne Muscular Dystrophy
    Campbell, Craig
    Shieh, Perry
    Sejersen, Thomas
    Luo, Xiaohui
    Elfring, Gary
    Kroger, Hans
    Riebling, Peter
    Ong, Tuyen
    Spiegel, Robert
    Peltz, Stuart
    Wong, Brenda
    NEUROLOGY, 2016, 86
  • [9] Long-term effect of ataluren in fourteen patients with nonsense mutation Duchenne muscular dystrophy
    Ortez, C.
    Medina, J.
    Vigo, M.
    Moya, O.
    Padros, N.
    Natera De Benito, D.
    Carrera, L.
    Colomer, J.
    Zschaeck, I.
    Jimenez-Mallebrera, C.
    Sole, L.
    Cubells, M.
    Jou, C.
    Nascimento, A.
    NEUROMUSCULAR DISORDERS, 2018, 28 : S63 - S63
  • [10] Ataluren delays loss of ambulation and respiratory decline in nonsense mutation Duchenne muscular dystrophy patients
    McDonald, Craig M.
    Muntoni, Francesco
    Penematsa, Vinay
    Jiang, Joel
    Kristensen, Allan
    Bibbiani, Francesco
    Goodwin, Elizabeth
    Gordish-Dressman, Heather
    Morgenroth, Lauren
    Werner, Christian
    Li, James
    Able, Richard
    Trifillis, Panayiota
    Tulinius, Mar
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 11 (03) : 139 - 155